Revenue grew 2.6% at constant currency to €3,574 million, driven by Biopharma, while adjusted EBITDA margin remained strong at 23.9%. Net profit rose to €227 million, supported by operational efficiency and lower financing costs after refinancing. Strategic initiatives included US plasma center closures, progress in self-sufficiency projects, and a potential US Biopharma IPO.
Original document:
This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.